A squalamine derivative, NV669, as a novel PTP1B inhibitor: in vitro and in vivo effects on pancreatic and hepatic tumor growth

• Published in: Oncotarget Vol. 10; no. 62; pp. 6651 - 6667
• Main Authors: Carmona, Sylvie, Brunel, Jean-Michel, Bonier, Rénaté, Sbarra, Véronique, Robert, Stéphane, Borentain, Patrick, Lombardo, Dominique, Mas, Eric, Gerolami, René
• Format: Journal Article
• Language: English
• Published: United States Impact journals 19.11.2019; Impact Journals LLC
• Subjects: Cancer; Chemical Sciences; Human health and pathology; Hépatology and Gastroenterology; Life Sciences; Medicinal Chemistry; Research Paper; cancer; PTP1B; aminosterol; liver; pancreas
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.27286

NV669 is an aminosterol derived from squalamine found to possess strong anticancer effects. The aim of this study was to investigate NV669's beneficial effects on human pancreatic and hepatic cancer models and to decipher the cellular and molecular mechanisms involved in tumor growth decrease upon treatment with NV669. Pancreatic (BxPC3, MiaPaCa-2) and hepatic (HepG2, Huh7) cancer cells were treated with NV669, and the effects recorded on proliferation, cell cycle and death. Results showed that NV669 inhibited the viability of cancer cells, induced cell cycle arrest and subsequently promoted apoptosis. This was accompanied by a decrease in the expression of cyclin B1 and phosphorylated Cdk1 and by a cleavage of pro-apoptotic caspase-8 and PARP-1. Taken together, our studies showed that NV669 inhibits the proliferation of pancreatic and hepatic cancer cells through the regulation of G2/M phase transition the cyclin B1-Cdk1 complex. NV669 inhibits PTP1B activity and FAK expression. NV669 impacts on the expression of adhesion molecules CDH-1, -2 and -3 in BxPC3 and Huh7 lines that form cell monolayers. Consecutively NV669 induces cell detachment. This suggests that NV669 by inhibiting PTP1B induces cell detachment and apoptosis. Subsequently, our results showed that NV669 inhibited the growth of pancreatic and hepatic tumor xenografts with a significant cell cycle arrest in pre-mitotic phase and an increase of tumor cell apoptosis. Therefore, NV669 may serve as an alternative anticancer agent, used alone or in association with other medications, for the treatment of pancreatic adenocarcinoma and hepatocellular carcinoma.